(Total Views: 292)
Posted On: 12/09/2019 12:33:47 PM
Post# of 154807
I think mds are going to love the sales pitch for combo HIV. (These ranking and this pitch are my own opinions right now of course).
Ranked #1 highest barrier to resistance on any HIV drug; could be first monotherapy approved drug in HIV. #2 would be Dolutegravir, but it failed its mono p3 trial due to HIV mutation.
-Ranked #1 lowest side effects; no serious side effects or SAE in over 800 patients. No discontinuing to AEs. Negligible toxicity in 830 patients.
-Tied #1 weekly dosing ( weekly self injectable sq injection) Tied would be monthly cabotegravir and rilpivine IM injection done by a provider. Yeah, I would prefer a weekly sq done myself over monthly more painful IM done by provider, but just for benefit of doubt I put tied.
-Patients that forgot to take their pills one day with combo should be covered with weekly leronlimab.
-No drug-food interactions, and low drug-drug interactions
Disadvantages
-Only works with R5 HIV, about 70% of population; requires test to verify
-sq injection
Ranked #1 highest barrier to resistance on any HIV drug; could be first monotherapy approved drug in HIV. #2 would be Dolutegravir, but it failed its mono p3 trial due to HIV mutation.
-Ranked #1 lowest side effects; no serious side effects or SAE in over 800 patients. No discontinuing to AEs. Negligible toxicity in 830 patients.
-Tied #1 weekly dosing ( weekly self injectable sq injection) Tied would be monthly cabotegravir and rilpivine IM injection done by a provider. Yeah, I would prefer a weekly sq done myself over monthly more painful IM done by provider, but just for benefit of doubt I put tied.
-Patients that forgot to take their pills one day with combo should be covered with weekly leronlimab.
-No drug-food interactions, and low drug-drug interactions
Disadvantages
-Only works with R5 HIV, about 70% of population; requires test to verify
-sq injection
(2)
(0)
